FDA lifts partial clinical hold on CheckMate-602 trial in MM

4 June 2018
2019_biotech_test_vial_discovery_big

The US Food and Drug Administration has lifted a partial clinical hold placed on CA209-602 (CheckMate-602), a randomized, open-label Phase III study evaluating the addition of Opdivo (nivolumab) to pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM), being conducted by US pharma major Bristol-Myers Squibb (NYSE: BMY).

The decision follows consultation with the FDA and agreement on amendments to the study protocol, stated the company, whose shares rose nearly 1% to $53.40 on the news Friday.

Three trials evaluating Opdivo-based combinationsin relapsed or refractory multiple myeloma were placed on partial clinical hold in September 2017 as an FDA precaution following risks identified in trials studying another anti–PD-1 agent, pembrolizumab (Merck & Co Keytruda), in patients with multiple myeloma.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology